Big Flats, NY, September 21, 2015 – X-GEN Pharmaceuticals, after recently receiving FDA approval of their ANDA, announced they are marketing and distributing Hydralazine Hydrochloride Injection, USP. Hydralazine is used to treat severe essential hypertension when the drug cannot be given orally or when there is an urgent need to lower blood pressure.
The industry has experienced supply interruptions during the past year creating availability concerns for Hydralazine, which is on the World Health Organizations List of Essential Medicines needed in basic health systems. Accordingly, X-GEN has sought to bring Hydralazine to market as part of its long term strategy to offer a consistent customer experience through the development of generic alternatives. Corporate Vice President, Rob Liles commented that “Bringing Hydralazine to market is consistent with our core values as well as our strategic plans to grow the company with meaningful products that can improve the lives of patients and medical professionals.”
X-GEN Pharmaceuticals, Inc. is focused on the development, manufacture and delivery of specialty pharmaceutical products which serve the healthcare community as effective, generic treatment choices. X-GEN’s expanding product line offers a broad range of dosage forms including injectables, anti-infective solutions, oral solids, and inhalants. For further information about X-GEN Pharmaceuticals, call (866) 390-4411, or visit the web-site at www.x-gen.us.